Targan, S. R. et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn’s disease. N. Engl. J. Med. 337, 1029–1035 (1997).

Article  CAS  PubMed  Google Scholar 

Torres, J. et al. ECCO guidelines on therapeutics in Crohn’s disease: medical treatment. J. Crohns Colitis 14, 4–22 (2020).

Article  PubMed  Google Scholar 

Raine, T. et al. ECCO guidelines on therapeutics in ulcerative colitis: medical treatment. J. Crohns Colitis 16, 2–17 (2022).

Article  PubMed  Google Scholar 

D’Haens, G. et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet 371, 660–667 (2008).

Article  PubMed  Google Scholar 

Khanna, R. et al. Early combined immunosuppression for the management of Crohn’s disease (REACT): a cluster randomised controlled trial. Lancet 386, 1825–1834 (2015).

Article  PubMed  Google Scholar 

Colombel, J. F. et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N. Engl. J. Med. 362, 1383–1395 (2010).

Article  CAS  PubMed  Google Scholar 

Panaccione, R. et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 146, 392–400.e3 (2014).

Article  CAS  PubMed  Google Scholar 

Colombel, J. F. et al. Effect of tight control management on Crohn’s disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet 390, 2779–2789 (2017).

Article  PubMed  Google Scholar 

Sandborn, W. J. et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 376, 1723–1736 (2017).

Article  CAS  PubMed  Google Scholar 

D’Haens, G. et al. Risankizumab as induction therapy for Crohn’s disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet 399, 2015–2030 (2022).

Article  PubMed  Google Scholar 

Danese, S. et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet 399, 2113–2128 (2022).

Article  CAS  PubMed  Google Scholar 

Ferrante, M. et al. Risankizumab as maintenance therapy for moderately to severely active Crohn’s disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. Lancet 399, 2031–2046 (2022).

Article  CAS  PubMed  Google Scholar 

Loftus, E. V. Jr. et al. Upadacitinib induction and maintenance therapy for Crohn’s disease. N. Engl. J. Med. 388, 1966–1980 (2023).

Article  CAS  PubMed  Google Scholar 

Sandborn, W. J. et al. Ozanimod as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 385, 1280–1291 (2021).

Article  CAS  PubMed  Google Scholar 

Sandborn, W. J. et al. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies. Lancet 401, 1159–1171 (2023).

Article  PubMed  Google Scholar 

Sands, B. E. et al. Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis. N. Engl. J. Med. 381, 1215–1226 (2019).

Article  CAS  PubMed  Google Scholar 

Danese, S. et al. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study. Lancet Gastroenterol. Hepatol. 7, 118–127 (2022).

Article  PubMed  Google Scholar 

Rubin, D. T. et al. Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials. Lancet Gastroenterol. Hepatol. 7, 17–27 (2022).

Article  PubMed  Google Scholar 

Feagan, B. G. et al. Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial. Lancet Gastroenterol. Hepatol. 8, 307–320 (2023).

Article  PubMed  Google Scholar 

Peyrin-Biroulet, L. et al. Risankizumab versus ustekinumab for moderate-to-severe Crohn’s disease. N. Engl. J. Med. 391, 213–223 (2024).

Article  CAS  PubMed  Google Scholar 

Sands, B. E. et al. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn’s disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. Lancet 399, 2200–2211 (2022).

Article  CAS  PubMed  Google Scholar 

Wasmann, K. A. et al. Treatment of perianal fistulas in Crohn’s disease, seton versus anti-TNF versus surgical closure following anti-TNF [PISA]: a randomised controlled trial. J. Crohns Colitis 14, 1049–1056 (2020).

Article  PubMed  PubMed Central  Google Scholar 

Meima-van Praag, E. M. et al. Short-term anti-TNF therapy with surgical closure versus anti-TNF therapy in the treatment of perianal fistulas in Crohn’s disease (PISA-II): a patient preference randomised trial. Lancet Gastroenterol. Hepatol. 7, 617–626 (2022).

Article  PubMed  Google Scholar 

Ponsioen, C. Y. et al. Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn’s disease: a randomised controlled, open-label, multicentre trial. Lancet Gastroenterol. Hepatol. 2, 785–792 (2017).

Article  PubMed  Google Scholar 

Luglio, G. et al. Surgical prevention of anastomotic recurrence by excluding mesentery in Crohn’s disease: the SuPREMe-CD study – a randomized clinical trial. Ann. Surg. 272, 210–217 (2020).

Article  PubMed  Google Scholar 

Hanauer, S. B. et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology 130, 323–333 (2006).

Article  CAS  PubMed  Google Scholar 

Reinisch, W. et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 60, 780–787 (2011).

Article  CAS  PubMed  Google Scholar 

Hanauer, S. B. et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 359, 1541–1549 (2002).

Article  CAS  PubMed  Google Scholar 

Colombel, J. F. et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology 132, 52–65 (2007).

Article  CAS  PubMed  Google Scholar 

Schreiber, S. et al. Maintenance therapy with certolizumab pegol for Crohn’s disease. N. Engl. J. Med. 357, 239–250 (2007).

Article  CAS  PubMed  Google Scholar 

Sandborn, W. J. et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 142, 257–265.e1–3 (2012).

Article  CAS  PubMed  Google Scholar 

Rutgeerts, P. et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 353, 2462–2476 (2005).

Article  CAS  PubMed  Google Scholar 

Sandborn, W. J. et al. Certolizumab pegol for the treatment of Crohn’s disease. N. Engl. J. Med. 357, 228–238 (2007).

Article  CAS  P